We refer to the announcement by Duopharma Biotech Berhad (hereinafter referred to as “Duopharma Biotech” or the “Company”) on 25 April 2022 (hereinafter referred to as the “Announcement”) in relation to the acceptance by the Government of Malaysia (hereinafter referred to as the “Government”) of the tender offer for the supply of the Products by Duopharma Marketing Sdn. Bhd. (hereinafter referred to as “DMktg”) (a wholly-owned subsidiary of Duopharma Biotech) and Biocon Sdn Bhd. (hereinafter referred to as “Biocon”) to the Government under the Ministry of Health’s procurement by way of direct negotiation (hereinafter referred to as the “Revised Letter of Award”). For consistency purposes, the abbreviations used in this announcement are the same as those previously defined in the Announcement unless otherwise defined herein.

The Company wishes to announce that pursuant to the Revised Letter of Award, the formal agreement for the procurement via direct negotiation for the supply of insulin medicine as a package (‘Perjanjian Perolehan Secara Rundingan Terus Pembekalan Ubat Insulin Secara Pakej’) (hereinafter referred to as the “Agreement”) between the Government, DMktg as the Supplier/Distributor and Biocon as the manufacturer has been executed on 30 September 2022.

The Agreement entered into by the Government, DMktg and Biocon for the supply of the Products is in the ordinary course of business of the Duopharma Biotech group.

For full details of the announcement, please refer to the attached file.

This announcement is dated 30 September 2022.